• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

揭示 ATP 与 EGFR、L858R,以及 T790M 和 L858R/T790 突变体结合机制的结构见解。

Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.

机构信息

Laboratorio de Modelado Molecular, Bioinformática y Diseño de Fármacos de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis Y Díaz Mirón S/N, Col. Casco de Santo Tomas , México City , México.

出版信息

J Biomol Struct Dyn. 2019 Oct;37(17):4671-4684. doi: 10.1080/07391102.2018.1558112. Epub 2019 Jan 11.

DOI:10.1080/07391102.2018.1558112
PMID:30558477
Abstract

The L858R mutation in EGFR is particularly responsive to small tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. This efficacy decreases due to drug resistance conferred by a second mutation, T790M, which subsequently produces a double mutant, L858R/T790M. Although this resistance was initially attributed to steric blocking by the T790M mutation, experimental studies have demonstrated that differences in the binding affinities of TKIs to T790M and L858R/T790M mutants are more a result of the increased sensitivity of these mutants to ATP than to a decrease in the affinity to TKIs. Regrettably, detailed information at the atomic level on the origins of the increased binding affinity of mutants for ATP is lacking. In this study, we have combined structural data and molecular dynamics simulations with the MMGBSA approach to determine how the L858R, T790M and L858R/T790 mutations impact the binding mechanism of ATP with respect to wild-type EGFR. Structural and energetic analyses provided novel information that helps to explain the increased affinity of ATP to T790M and L858R/T790 mutants with respect to L858R and wild-type systems. In addition, it was observed that dimerization of the wild-type and mutant systems exerts dissimilar effects on the ATP binding affinity characteristic of negative cooperativity. Communicated by Ramaswamy H. Sarma.

摘要

EGFR 中的 L858R 突变特别对小的酪氨酸激酶抑制剂(TKI)如吉非替尼和厄洛替尼敏感。这种疗效由于第二个突变 T790M 导致的耐药性而降低,这随后产生了一个双突变体,L858R/T790M。虽然这种耐药性最初归因于 T790M 突变的空间位阻,但实验研究表明,TKI 与 T790M 和 L858R/T790M 突变体的结合亲和力的差异更多地是由于这些突变体对 ATP 的敏感性增加,而不是 TKI 亲和力的降低。遗憾的是,关于突变体对 ATP 结合亲和力增加的原子水平的详细信息尚不清楚。在这项研究中,我们结合结构数据和分子动力学模拟以及 MMGBSA 方法,确定了 L858R、T790M 和 L858R/T790M 突变如何影响野生型 EGFR 中 ATP 的结合机制。结构和能量分析提供了新的信息,有助于解释 T790M 和 L858R/T790 突变体与 L858R 和野生型系统相比对 ATP 的亲和力增加。此外,观察到野生型和突变型系统的二聚化对负协同作用特征的 ATP 结合亲和力产生了不同的影响。由 Ramaswamy H. Sarma 传达。

相似文献

1
Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.揭示 ATP 与 EGFR、L858R,以及 T790M 和 L858R/T790 突变体结合机制的结构见解。
J Biomol Struct Dyn. 2019 Oct;37(17):4671-4684. doi: 10.1080/07391102.2018.1558112. Epub 2019 Jan 11.
2
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.表皮生长因子受体(EGFR)激酶中的T790M突变通过增加对三磷酸腺苷(ATP)的亲和力导致耐药性。
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5. doi: 10.1073/pnas.0709662105. Epub 2008 Jan 28.
3
Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis.通过结构和能量分析研究激酶抑制剂与 EGFR 及 T790M、L858R 和 L858R/T790M 突变体的结合机制。
Int J Biol Macromol. 2018 Oct 15;118(Pt B):1948-1962. doi: 10.1016/j.ijbiomac.2018.07.042. Epub 2018 Jul 12.
4
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.用突变选择性变构抑制剂克服EGFR(T790M)和EGFR(C797S)耐药性。
Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.
5
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.表皮生长因子受体(EGFR)与ErbB-3异源二聚化在非小细胞肺癌治疗中对EGFR突变诱导的吉非替尼和厄洛替尼耐药性的作用
PLoS One. 2015 May 20;10(5):e0128360. doi: 10.1371/journal.pone.0128360. eCollection 2015.
6
Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations.通过绝对结合自由能计算揭示表皮生长因子受体激酶中T790M突变导致耐药的机制
Front Mol Biosci. 2022 May 30;9:922839. doi: 10.3389/fmolb.2022.922839. eCollection 2022.
7
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.针对野生型、L858R/T790M 以及 L858R/T790M/C797S 三种形式的 EGFR,三种代次的酪氨酸激酶抑制剂的结构动力学和激酶抑制活性。
Comput Biol Med. 2022 Aug;147:105787. doi: 10.1016/j.compbiomed.2022.105787. Epub 2022 Jun 28.
8
Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.针对表皮生长因子受体(EGFR)酪氨酸激酶的吉非替尼和奥希替尼耐药的分子机制研究:分子动力学和结合自由能计算。
J Biomol Struct Dyn. 2023 Jul;41(10):4534-4548. doi: 10.1080/07391102.2022.2068650. Epub 2022 May 4.
9
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.非小细胞肺癌相关人类表皮生长因子受体突变体药物敏感性改变的结构基础。
Oncogene. 2013 Jan 3;32(1):27-38. doi: 10.1038/onc.2012.21. Epub 2012 Feb 20.
10
Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.表皮生长因子受体(EGFR)突变体的蛋白质稳定性差异决定了对酪氨酸激酶抑制剂的反应性。
Oncotarget. 2016 Oct 18;7(42):68597-68613. doi: 10.18632/oncotarget.11860.

引用本文的文献

1
A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N.一种用于快速预测表皮生长因子受体(EGFR)过度激活的分子动力学方案及其在罕见突变S768I、S768N、D761N中的应用
Comput Struct Biotechnol J. 2025 Jul 30;27:3370-3378. doi: 10.1016/j.csbj.2025.07.046. eCollection 2025.
2
Epithelial-mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC).上皮-间质转化(EMT)及其在非小细胞肺癌(NSCLC)获得性表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)化疗耐药中的作用。
Cancer Pathog Ther. 2024 Jul 6;3(3):215-225. doi: 10.1016/j.cpt.2024.07.001. eCollection 2025 May.
3
Insight into the inhibitory activity of mangiferin and Silybin against HER2 and EGFR using theoretical and experimental approaches.运用理论和实验方法深入探究芒果苷和水飞蓟宾对HER2和EGFR的抑制活性。
Sci Rep. 2025 Mar 13;15(1):8658. doi: 10.1038/s41598-025-93612-2.
4
Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway.脱氧布瓦西丁 - 葡萄糖苷通过靶向表皮生长因子受体/间质 - 上皮转化因子(EGFR/MET)和蛋白激酶B(AKT)信号通路诱导非小细胞肺癌细胞凋亡。
EXCLI J. 2024 Oct 21;23:1287-1302. doi: 10.17179/excli2024-7359. eCollection 2024.
5
Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells.脱氧博伐他汀通过靶向 EGFR、MET 和 AKT 信号通路抑制非小细胞肺癌细胞。
Sci Rep. 2024 Sep 6;14(1):20820. doi: 10.1038/s41598-024-70823-7.
6
Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations.咪唑并[1,5-a]吡啶衍生物作为 EGFR 酪氨酸激酶抑制剂的揭示:伞状采样和导向分子动力学模拟。
Sci Rep. 2024 May 28;14(1):12218. doi: 10.1038/s41598-024-62743-3.
7
Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review.针对(C797S)表皮生长因子受体(EGFR)突变的第四代选择性抑制剂对抗非小细胞肺癌耐药性的见解:一项批判性综述
RSC Adv. 2023 Jun 21;13(27):18825-18853. doi: 10.1039/d3ra02347h. eCollection 2023 Jun 15.
8
Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations.通过绝对结合自由能计算揭示表皮生长因子受体激酶中T790M突变导致耐药的机制
Front Mol Biosci. 2022 May 30;9:922839. doi: 10.3389/fmolb.2022.922839. eCollection 2022.
9
Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.通过靶向表皮生长因子受体/人表皮生长因子受体2将美国食品药品监督管理局批准的药物化合物用于治疗乳腺癌
Pharmaceuticals (Basel). 2021 Aug 12;14(8):791. doi: 10.3390/ph14080791.
10
Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.新型酚类化合物作为潜在的双重 EGFR 和 COX-2 抑制剂:设计、半合成、体外生物学评价及计算机模拟研究。
Drug Des Devel Ther. 2021 May 31;15:2325-2337. doi: 10.2147/DDDT.S310820. eCollection 2021.